Diagnostic Value of Bcl-2, miR-451 and Th17 Cells in Esophageal Cancer and Their Relation with Recurrence

CHEN Lianlian; ZHU Chunkai; ZHENG Peiming

doi:10.3971/j.issn.1000-8578.2021.20.0292

Cancer Research on Prevention and Treatment > 2021 > 48(1): 38-42. > DOI: 10.3971/j.issn.1000-8578.2021.20.0292

CHEN Lianlian, ZHU Chunkai, ZHENG Peiming. Diagnostic Value of Bcl-2, miR-451 and Th17 Cells in Esophageal Cancer and Their Relation with Recurrence[J]. Cancer Research on Prevention and Treatment, 2021, 48(1): 38-42. DOI: 10.3971/j.issn.1000-8578.2021.20.0292

Citation:

PDF (2953 KB)

Diagnostic Value of Bcl-2, miR-451 and Th17 Cells in Esophageal Cancer and Their Relation with Recurrence

1.
Department of Laboratory, Affiliated Hospital of He'nan Academy of Traditional Chinese Medicine, Zhengzhou 450000, China
2.
Department of Laboratory, He'nan People's Hospital, Zhengzhou 450000, China

Funding:

National Natural Science Foundation of China 81802094

More Information

Received Date: April 01, 2020
Revised Date: July 18, 2020
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the diagnostic value of Bcl-2, miR-451 and Th17 cells in esophageal cancer and their relation with recurrence.
Methods
We selected 101 patients with esophageal cancer as the experimental group and 95 healthy patients as the control group. The correlation between the clinicopathological characteristics and the level of each peripheral blood index was analyzed. The ROC curve was used to analyze the diagnostic value of each peripheral blood index. Multiple linear regression analysis was used to analyze the relation between each index and tumor recurrence.
Results
Peripheral blood Bcl-2, miR-451 and Th17 cells in the experimental group were higher than those in the control group (all P < 0.05); differentiation degree, clinical stage, tumor diameter and lymph node metastasis were positively correlated with the levels of Bcl-2, miR-451, and Th17 cells (all P < 0.05). Bcl-2, miR-451 and Th17 cells in relapsed patients were higher than those in non-relapsed patients (all P < 0.05); after controlling other factors such as differentiation degree, clinical stage, tumor size and lymph node metastasis, the levels of Bcl-2, miR-451 and Th17 cells were significantly correlated with recurrence (all P < 0.05).
Conclusion
Bcl-2, miR-451 and Th17 cells in peripheral blood of esophageal cancer patients are abnormally expressed and their expression are closely related to differentiation degree, clinical stage and recurrence. The combined detection could provide an objective basis for clinical diagnosis and prognosis assessment.
- B-lymphoma-2 gene,
- MicroRNA-451,
- T helper cells 17,
- Esophageal cancer,
- Recurrence,
- Receiver operating characteristic curve

FullText(HTML)

References (18)

References

[1]	Andreou A, Pesthy S, Struecker B, et al. Incidence and Risk Factors of Symptomatic Hiatal Hernia after Resection for Gastric and Esophageal Cancer[J]. Anticancer Res, 2017, 37(12): 7031-7036. doi: 10.1016/j.jamcollsurg.2016.08.547
[2]	朱珠, 刘晴, 庹吉妤, 等.柴湖地区食管癌及癌前病变风险评估模型建立[J].现代预防医学, 2019, 46(15): 2701-2704, 2712. https://www.cnki.com.cn/Article/CJFDTOTAL-XDYF201915004.htm Zhu Z, Liu Q, Tuo JY, et al. Establishment of risk assessment model for esophageal cancer and precancerous lesions, Chaihu[J]. Xian Dai Yu Fang Yi Xue, 2019, 46(15): 2701-2704, 2712. https://www.cnki.com.cn/Article/CJFDTOTAL-XDYF201915004.htm
[3]	Nguyen T, Bartscht T, Schild SE, et al. A Scoring Tool to Estimate the Survival of Elderly Patients With Brain Metastases from Esophageal Cancer Receiving Whole-brain Irradiation[J].Anticancer Res, 2020, 40(3): 1661-1664. doi: 10.21873/anticanres.14116
[4]	Deswaerte V, Nguyen P, West A, et al. Inflammasome Adaptor ASC Suppresses Apoptosis of Gastric Cancer Cells by an IL18-Mediated Inflammation-Independent Mechanism[J]. Cancer Res, 2018, 78(5): 1293-1307. doi: 10.1158/0008-5472.CAN-17-1887
[5]	Inoue-Yamauchi A, Jeng PS, Kim K, et al. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy[J]. Nat Commun, 2017, 8: 16078. doi: 10.1038/ncomms16078
[6]	Wang WC, Hang CW, Zhang YQ, et al. Dietary miR-451 protects erythroid cells from oxidative stress via increasing the activity of Foxo3 pathway[J]. Oncotarget, 2017, 8(63): 107109-107124. doi: 10.18632/oncotarget.22346
[7]	Wang Y, Xu G, Wang J, et al. Relationship of Th17/Treg Cells and Radiation Pneumonia in Locally Advanced Esophageal Carcinoma[J]. Anticancer Res, 2017, 37(8): 4643-4647. doi: 10.21873/anticanres.11866
[8]	Short MW, Burgers KG, Fry VT. Esophageal Cancer[J]. Am Fam Physician, 2017, 95(1): 22-28.
[9]	Shen Y, Gong JM, Zhou LL, et al. Correction: MiR-451 as a new tumor marker for gastric cancer[J].Oncotarget, 2019, 10(59): 6396. doi: 10.18632/oncotarget.27291
[10]	荣忠厚, 苏忠学, 耿文茂, 等.微小RNA-451表达和胃癌临床病理特征及预后的关系[J].中华实验外科杂志, 2016, 33(2): 318-320. doi: 10.3760/cma.j.issn.1001-9030.2016.02.013 Rong ZH, Su ZX, Geng WM, et al. The relations between expression quantity of microRNA-451 and clinicopathological features and prognosis in gastric cancer[J]. Zhonghua Shi Yan Wai Ke Za Zhi, 2016, 33(2): 318-320. doi: 10.3760/cma.j.issn.1001-9030.2016.02.013
[11]	陈志平, 林志彬, 邹文兵, 等.微小RNA-451靶向调控c-Myc影响结肠癌细胞的增殖与凋亡[J].中华实验外科杂志, 2019, 36(4): 660-662. doi: 10.3760/cma.j.issn.1001-9030.2019.04.022 Chen ZP, Lin ZB, Zou WB, et al. Effect of microRNA-451 on proliferation and apoptosis of colon cancer cells via targeting regulation of c-Myc[J]. Zhonghua Shi Yan Wai Ke Za Zhi, 2019, 36(4): 660-662. doi: 10.3760/cma.j.issn.1001-9030.2019.04.022
[12]	Ni XB, Ou CW, Guo JB, et al. Lentiviral vector-mediated co-overexpression of VEGF and Bcl-2 improves mesenchymal stem cell survival and enhances paracrine effects in vitro[J]. Int J Mol Med, 2017, 40(2): 418-426. doi: 10.3892/ijmm.2017.3019
[13]	檀碧波, 李勇, 范立侨, 等.胃癌组织对奥沙利铂化疗敏感性及其与微小RNA-150表达的关系[J].中华实验外科杂志, 2018, 35(10): 1934-1936. doi: 10.3760/cma.j.issn.1001-9030.2018.10.047 Tan BB, Li Y, Fan LQ, et al. Relationship between drug sensitivity of gastric cancer tissues to L-oxaliplatin and microRNA-150[J]. Zhonghua Shi Yan Wai Ke Za Zhi, 2018, 35(10): 1934-1936. doi: 10.3760/cma.j.issn.1001-9030.2018.10.047
[14]	杜兰宁, 王丽娜, 李淑萍. p53和Bcl-2在食管鳞癌组织中的表达及与放化疗疗效的关系[J].兰州大学学报(医学版), 2016, 42(4): 43-46. https://www.cnki.com.cn/Article/CJFDTOTAL-LZYX201604010.htm Du LN, Wang LN, Li SP. Expression of p53, Bcl-2 in esophageal squamous cancer tissues and their relationship with chemoradiotherapy efficacy[J]. Lanzhou Da Xue Xue Bao (Yi Xue Ban), 2016, 42(4): 43-46. https://www.cnki.com.cn/Article/CJFDTOTAL-LZYX201604010.htm
[15]	Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity[J]. Cell Mol Immunol, 2018, 15(5): 458-469. doi: 10.1038/s41423-018-0004-4
[16]	Liu F, Bu ZY, Zhao F, et al. Increased T-helper 17 cell differentiation mediated by Exosome-mediated miR-451 redistribution in gastric cancer infiltrated T cells[J]. Cancer Sci, 2018, 109(1): 65-73. doi: 10.1111/cas.13429
[17]	Purvis HA, Clarke F, Jordan CK, et al. Protein Tyrosine Phosphatase PTPN22 regulates IL dependent Th17 responses by modulating dectinsignaling in mice[J]. Eur J Immunol, 2018, 48(2): 306-315. doi: 10.1002/eji.201747092
[18]	Koerner J, Brunner T, Groettrup M. Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice[J]. Oncotarget, 2017, 8(31): 50873-50888. doi: 10.18632/oncotarget.15141

[1]	SHAN Baoen. Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era[J]. Cancer Research on Prevention and Treatment, 2023, 50(9): 833-841. DOI: 10.3971/j.issn.1000-8578.2023.22.1423
[2]	QIAO Shishi, KONG Tiandong, YU Dan, YANG Zhen, PAN Yanfeng, ZHAO Lingdi. A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 293-297. DOI: 10.3971/j.issn.1000-8578.2023.22.0852
[3]	YAN Guangning, YU Ling, LAI Xuwen, YE Danli, WANG Wei, WANG Zhuocai. Correlation Between PD-1/CTLA-4 Expressions with C linicopathological Features and Prognosis of Osteosarcoma Patients[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 63-68. DOI: 10.3971/j.issn.1000-8578.2023.22.0483
[4]	QI Lin, ZHANG Zhao, WANG Suyun, LIU Guimin, WANG Rui, FU Jianzhu, CHENG Zhiyong. Effect of Rapamycin on Exosomes and PD-1/PD-L1 in Human Erythroleukemia HEL Cells[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 1021-1027. DOI: 10.3971/j.issn.1000-8578.2022.22.0188
[5]	CHANG Jinyi, WANG Wei, CAI Haifeng. Research Progress of PD-1/PD-L1 Inhibitor Combined with Trastuzumab in HER2-positive Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 965-969. DOI: 10.3971/j.issn.1000-8578.2022.21.1462
[6]	LAI Yanliang, GENG Yan, YANG Bingquan. Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1035-1040. DOI: 10.3971/j.issn.1000-8578.2021.21.0365
[7]	YU Lin, LI Guangping, ZHOU Changyu, FU Huaying. Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 794-798. DOI: 10.3971/j.issn.1000-8578.2021.20.1449
[8]	MA Yinjuan, YANG Xiaying, WANG Ying, WANG Xuan, PAN Yaozhu. Research Progress of PD-1/PD-L1/2 Pathway in Multiple Myeloma[J]. Cancer Research on Prevention and Treatment, 2021, 48(6): 647-651. DOI: 10.3971/j.issn.1000-8578.2021.21.0108
[9]	WANG Yufeng, YAO Nan, WANG Jun, MIN Guangtao. Prognostic Role of PD-1 and PD-L1 Expression in Gastric Cancer Patients: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2020, 47(5): 346-352. DOI: 10.3971/j.issn.1000-8578.2020.19.0950
[10]	ZOU Hanhui, Li Tao. Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(2): 141-146. DOI: 10.3971/j.issn.1000-8578.2020.19.0945

Cited By

Cited by

Periodical cited type(12)

1.	梅琪，袁牧，钱景瑜，刘若宇，谭玉林. 肝动脉化疗栓塞术联合卡瑞利珠及阿帕替尼治疗中晚期肝癌的安全性及临床疗效观察. 蚌埠医学院学报. 2024(01): 51-54+58 .
2.	李丽敏，王璐，曹阳博，刘栋利，陈鹏飞. 肝癌患者经导管动脉化疗栓塞后发生栓塞综合征的影响因素分析. 癌症进展. 2024(01): 72-75 .
3.	费睿成，亓民. PD-1单抗联合TACE对晚期原发性肝癌患者的治疗效果. 实用中西医结合临床. 2024(10): 16-19 .
4.	刘小梅，钟梅，刘浩，易军，王洪云. 晚期肝癌免疫相关治疗的获益和不良反应临床研究. 基层医学论坛. 2023(19): 20-22+35 .
5.	何晓锐，王淑红. 阿替利珠单抗联合贝伐珠单抗治疗晚期肝癌的临床效果. 临床医学研究与实践. 2023(27): 29-32 .
6.	陈方红，刘娱，边界. PD-1抑制剂治疗肝癌患者的临床疗效及ECOG-PS评分联合Child-Pugh分级对肿瘤超进展的预测价值. 广西医学. 2023(15): 1800-1806 .
7.	郭稳稳，程昌盛，吴燕，林文东，赖辉强，黄吉荣，龙高云. 安罗替尼治疗晚期肝癌的疗效及预后的影响因素. 临床与病理杂志. 2022(08): 1822-1828 .
8.	殷云飞，鲁邱阳. 抗PD-1单抗对中晚期肝癌患者近期疗效、外周血T淋巴细胞亚群指标的影响. 中国医学创新. 2021(13): 19-22 .
9.	李冰妍，陈林会，郑颖娟，梁天嵩，杨道科. 程序性死亡受体1抑制剂治疗远处转移鼻咽癌疗效观察. 肿瘤基础与临床. 2021(03): 207-211 .
10.	朱风婷，曾江正，姜靖雯，陈学武，张慧. 卡瑞利珠单抗联合射频消融术及FOLFOX方案治疗原发性肝癌疗效研究. 中国药业. 2021(15): 38-41 .
11.	王俊旗，徐锋. 程序性死亡受体1及其配体PD-L1、细胞毒性T淋巴细胞相关抗原4抑制剂在晚期肝癌治疗中的进展. 中华普通外科学文献(电子版). 2021(04): 304-308 .
12.	鄢清元，熊巍，杨文平. 晚期肝癌患者索拉非尼分子靶向治疗的有效性及对疾病控制率的影响研究. 中国医学创新. 2021(29): 173-177 .

Other cited types(0)

Get Citation

PDF

XML

Article views (1078) PDF downloads (220) Cited by(12)

Turn off MathJax

Article Contents

Abstract

References

Diagnostic Value of Bcl-2, miR-451 and Th17 Cells in Esophageal Cancer and Their Relation with Recurrence